GPC3 and neoplasm: A second oncogenic signal, such as c-Met or glypican-3, is required for the Wnt/β-catenin pathway to contribute to HCC development; targeting these oncogenic signal molecules in combination with inhibition of the Wnt/β-catenin signaling promotes tumor regression.